Q11677 (Q11677): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed an Item)
(‎Removed claims)
Property / EU contribution
39,804,511.31 Czech koruna
Amount39,804,511.31 Czech koruna
UnitCzech koruna
 
Property / EU contribution: 39,804,511.31 Czech koruna / rank
Normal rank
 
Property / EU contribution
1,592,180.4524 Euro
Amount1,592,180.4524 Euro
UnitEuro
 
Property / EU contribution: 1,592,180.4524 Euro / rank
Preferred rank
 
Property / EU contribution: 1,592,180.4524 Euro / qualifier
exchange rate to Euro: 0.04 Euro
Amount0.04 Euro
UnitEuro
 
Property / EU contribution: 1,592,180.4524 Euro / qualifier
point in time: 1 October 2020
Timestamp+2020-10-01T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
 
Property / budget
61,769,881.0 Czech koruna
Amount61,769,881.0 Czech koruna
UnitCzech koruna
 
Property / budget: 61,769,881.0 Czech koruna / rank
Normal rank
 
Property / budget
2,470,795.24 Euro
Amount2,470,795.24 Euro
UnitEuro
 
Property / budget: 2,470,795.24 Euro / rank
Preferred rank
 
Property / budget: 2,470,795.24 Euro / qualifier
exchange rate to Euro: 0.04 Euro
Amount0.04 Euro
UnitEuro
 
Property / budget: 2,470,795.24 Euro / qualifier
point in time: 1 October 2020
Timestamp+2020-10-01T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
 

Revision as of 01:34, 12 February 2020

Project in Czech Republic financed by DG Regio
Language Label Description Also known as
English
No label defined
Project in Czech Republic financed by DG Regio

    Statements

    0 references
    64.439999989639 percent
    0 references
    31 October 2020
    0 references
    Institute of Applied Biotechnologies a.s.
    0 references

    50°5'1.93"N, 14°30'28.48"E
    0 references
    10800
    0 references
    10800
    0 references
    Jedná se o projekt vysoké technologické úrovně a vysoké míry inovace, který si klade za cíl významně zvýšit produktový potenciál společnosti Institute of Applied Biotechnologies a.s. (IAB) ve spolupráci s výzkumným partnerem Lékařskou fakultou Univerzity Palackého v Olomouci, jmenovitě Ústavem molekulární a translační medicíny (UMTM). Cílem je vývoj produktů pro prediktivní onkologickou diagnostiku založenou na cirkulujících buňkách / DNA / RNA. a. (Czech)
    0 references

    Identifiers

    CZ.01.1.02/0.0/0.0/17_107/0012422
    0 references